REGENXBIO Inc.
RGNX
$9.01
$0.9011.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 74.95% | 80.70% | -7.66% | -15.14% | -8.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 74.95% | 80.70% | -7.66% | -15.14% | -8.18% |
| Cost of Revenue | 7.16% | 13.51% | 11.05% | -112.90% | -110.93% |
| Gross Profit | 56.91% | 62.55% | -8.20% | 191.21% | 186.26% |
| SG&A Expenses | -4.97% | -11.71% | -18.42% | -17.30% | -11.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 179.28% | 176.97% | 117.88% | 101.03% | 102.28% |
| Total Operating Expenses | -3.50% | -9.43% | -11.31% | -8.33% | -7.14% |
| Operating Income | 32.25% | 39.49% | 12.55% | 5.66% | 6.76% |
| Income Before Tax | 27.22% | 39.42% | 13.86% | 8.30% | 12.02% |
| Income Tax Expenses | -- | -- | -- | -253.49% | -253.49% |
| Earnings from Continuing Operations | 27.17% | 39.38% | 13.81% | 8.34% | 12.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.17% | 39.38% | 13.81% | 8.34% | 12.07% |
| EBIT | 32.25% | 39.49% | 12.55% | 5.66% | 6.76% |
| EBITDA | 34.19% | 41.76% | 12.98% | 5.83% | 7.48% |
| EPS Basic | 34.76% | 47.12% | 23.49% | 15.84% | 16.62% |
| Normalized Basic EPS | 33.15% | 45.95% | 23.22% | 15.52% | 16.34% |
| EPS Diluted | 34.79% | 47.18% | 23.57% | 15.99% | 16.70% |
| Normalized Diluted EPS | 33.15% | 45.95% | 23.22% | 15.52% | 16.34% |
| Average Basic Shares Outstanding | 10.98% | 14.91% | 13.19% | 9.71% | 6.20% |
| Average Diluted Shares Outstanding | 11.02% | 14.95% | 13.19% | 9.71% | 6.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |